Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0524851
Disease: Neurodegenerative Disorders
Neurodegenerative Disorders 		0.020 Biomarker group BEFREE We demonstrate that systemically delivered and CNS-restricted rAAVs can serve as efficacious and sustained gene therapeutics in a model of a severe neurodegenerative disorder even when administered as late as P20. 23817205 2013
CUI: C0524851
Disease: Neurodegenerative Disorders
Neurodegenerative Disorders 		0.020 Biomarker group BEFREE Our finding describes the novel MANI-Cdc27-APC pathway as an important cascade that prevents neurons from extending axons, thus providing implications for the potential treatment of neurodegenerative diseases. 20716133 2011
CUI: C0013264
Disease: Muscular Dystrophy, Duchenne
Muscular Dystrophy, Duchenne 		0.020 Biomarker disease BEFREE Identification of Duchenne muscular dystrophy genomic probe P20 constant Taql fragment corresponding to the EcoRV and Mspl polymorphisms. 1709287 1991
CUI: C0013264
Disease: Muscular Dystrophy, Duchenne
Muscular Dystrophy, Duchenne 		0.020 Biomarker disease BEFREE Together, these properties make P20 useful for carrier detection, prenatal diagnosis, and the study of deletion induction in both DMD and BMD. 2900805 1988
CUI: C0239946
Disease: Fibrosis, Liver
Fibrosis, Liver 		0.010 AlteredExpression disease BEFREE However, NLRP6<sup>-</sup><sup>/</sup><sup>-</sup> mice showed more severe liver damage and liver fibrosis after transplantation together with higher level of phosphorylated Iκbα, phosphorylated p38-MAPK, Pro-caspase-1, p20 expression as well as IL-1β, IL-18, IL-6, and TNF-α secretion compared with wide-type. 31301646 2019
CUI: C0239981
Disease: Hypoalbuminemia
Hypoalbuminemia 		0.010 Biomarker disease BEFREE In the 14 patients with severe kidney dysfunction and hypoalbuminemia, none of the coefficients had a P20 accuracy greater than 45%. 31067355 2019
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.010 AlteredExpression disease BEFREE Exogenous administration of N-Acetyl-L-cysteine (NAC), a small molecular inhibitor of ROS, remarkably suppressed caspase-1 p20 expression and IL-1β and IL-18 production in livers of Tim-3 KO mice, thus significantly reducing the severity of steatohepatitis induced by MCD. 29735977 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.010 Biomarker group BEFREE Additionally to the better tumor targeting and the in situ release of P20, it is expected that the therapeutic efficiency of the dual-peptide PLGA NPs was further enhanced by a synergistic effect between P20 and combined peptide C. Our encouraging results showed that by enabling the co-delivery of two peptides and promoting tumor targeting, PLGA NPs coupled with peptide C is a promising platform for peptide-based cancer therapy. 28547860 2017
CUI: C0752335
Disease: Neuropsychiatric Systemic Lupus Erythematosus
Neuropsychiatric Systemic Lupus Erythematosus 		0.010 Biomarker disease BEFREE Our data imply the Nogo-a/NgR1 pathway is involved in NPSLE. 28807492 2017
CUI: C1998028
Disease: Photoreceptor degeneration
Photoreceptor degeneration 		0.010 Biomarker disease BEFREE The Reep6-/- mice exhibited progressive photoreceptor degeneration from P20 onwards. 28475715 2017
CUI: C0017638
Disease: Glioma
Glioma 		0.010 Biomarker disease BEFREE While treatment with TRAIL alone caused partial processing of caspase-3 to its p20 intermediate in TRAIL-resistant glioma cell lines, co-treatment with TRAIL and subtoxic doses of paxilline caused complete processing of caspase-3 into its active subunits. 21150246 2011
CUI: C0917713
Disease: Becker Muscular Dystrophy
Becker Muscular Dystrophy 		0.010 Biomarker disease BEFREE Together, these properties make P20 useful for carrier detection, prenatal diagnosis, and the study of deletion induction in both DMD and BMD. 2900805 1988